Fortrea oncology: Large enough to serve in the UK, engaged enough to care

Over the past decade, there has been remarkable progress in oncology, driven by a deeper understanding of cancer biology and the integration of cutting-edge technologies.

Precision Oncology

Diagnostic Center of Excellence Team

Driving change in nephrology: PARASOL project leads to FDA acceptance of proteinuria

Designing the Future of Pediatric Rare Disease Trials for Cell and Gene Therapy

Bridging Innovation and Impact: Why Evidence Generation is the New Currency in Biotech

Discover how biotech companies strategically leverage medical evidence generation to demonstrate value, accelerate market access, and drive real-world impact.

Peter M. Neupert

Peter Neupert serves as Fortrea’s Chairman and Interim Chief Executive Officer.

Launching the Fortrea Podcast!

Dana Annunziato

Dana has more than 25 years of experience in the pharmaceutical and CRO industry, with 9 years at Fortrea.